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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not oral
dextromethorphan provides pain relief in patients with diabetic neuropathy.
Study Design: Review of three peer-reviewed, double blind, randomized control trials published
between 1995-2012.
Data Sources: Studies were selected through Cochrane Library Collection and PubMed and
chosen based on their relevance to the clinical question as well as their inclusion criteria;
including adults over the age of 18; and those who were experiencing daily pain of moderate
intensity, for at least half of the day, over a span of 3 months.
Outcomes Measured: Each RCT measured the same outcome but in a different way. In the
Nelson study, pain relief was measured using a13-word descriptor scale; for the Sani study, pain
relief was measured using a category rating scale; and the Shaibani trial measured pain relief
using a Pain Relief Rating scale.
Results: It was assessed and recorded in all three RTCs that the efficacy of oral
dextromethorphan in pain relief was statistically significant when compared to a placebo.
Conclusions: Oral dextromethorphan has been shown to give pain relief to patients with diabetic
neuropathy. With further research using larger sample sizes and assessment of long-term
adverse reactions, dextromethorphan may be made a common treatment for diabetic neuropathy.
Key Words: dextromethorphan, diabetic neuropathy, peripheral neuropathy

Lundberg,	
  Dextromethorphan	
  and	
  Diabetic	
  Neuropathy	
  	
   1	
  
INTRODUCTION
Diabetic neuropathy (DN) is a common complication of diabetes, where damage to
nerves leads to mild/severe disabling pain. It is hypothesized and suggested that diabetic
neuropathy is caused by an abnormal hyper excitability induced by excitatory neurotransmitters
(NT) such as glutamate and aspartate, which are dependent on activation of NMDA receptors1.
Therefore, current treatments have been based around drugs that block or inhibit NMDA
receptors1.
In the United States, ~25.8 million people are affected by diabetes (DM). Of that 25.8
million, ~25.6 million are over the age of 202. Between 60-70% of people with DM experience
some form of nerve damage, known as diabetic neuropathy. DN and its complications cost the
US between $4.6-$13.7 billion annually; most of these costs are attributed to Type 2 diabetics3.
There is not an exact estimate of how many health care visits result in caring for patients
suffering from diabetic neuropathy specifically; however, in 2008, 44,021 DM type 2 patients
were identified of getting a minimum of 12 months of continuous follow-up care and 32, 991
DM type 2 patients were found to have ~24 months of continuous health-plan enrollment4. The
majority of these patients had at least one physician office visit (99.8%), laboratory diagnostic
test (96.2%), and other outpatient visits (97.5%)4. Although the exact number of health care
visits for diabetic neuropathy is unknown, the costs are exponentially high.
Diabetic neuropathy is triggered by multiple factors. The six main factors that can
contribute to DN include: metabolic (ex. high blood glucose or long term diabetes);
neurovascular (ex. damage to blood vessels that carry oxygen/nutrients); autoimmune (ex.
inflammation to nerves); mechanical injury (ex. carpel tunnel); inherited traits (ex. nerve
disease); or lifestyle factors (ex. smoking or drinking) 5. Just like the causes of diabetic
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neurothapy are many, the types of diabetic neuropathy are numerous, as well. Diabetic
neuropathy can be broken down into four distinct classifications. These classifications include
peripheral, autonomic, proximal, and focal5. The most common subtype that people experience
is peripheral neuropathy. Peripheral neuropathy is characterized by pain or numbness felt in the
toes, feet, legs, hands, and/or arms5. Autonomic neuropathy causes alterations in organ functions
such as digestion, sexual response, perspiration, and bowel and bladder function5. Proximal
neuropathy, or the opposite of peripheral neuropathy, causes pain in the buttocks, thighs, and/or
hips5. This pain eventually causes weakness in the legs5. Finally, focal neuropathy results in a
sudden onset of pain in a specific nerve or nerve group5. These weak nerves lead to muscle
weakness and/or pain. In focal neuropathy, any nerve/nerve group can be affected5. The multiple
causes and forms of diabetic neuropathy highlights why this medical condition is interfering with
and affecting so many diabetics’ lives. Furthermore, this noted information explains why so
many healthcare hours and dollars are spent, each year, towards this medical complication.
Currently diabetic neuropathy is managed multiple ways. The first step to take in the
control of DN is managing blood sugar levels. Managing and controlling blood sugar levels
helps prevent further nerve damage5. The next phase in regulating DN is controlling the pain
associated with the nerve damage. Presently, a variety of medications are being used to alleviate
the patient’s discomfort. Common drugs used to treat the pain include tricyclic antidepressants
(ex: amitriptyline); antidepressants which include duloxetine, venlafaxine, bupropion,
paroxetine, and citalopram; anticonvulsants such as pregabalin or gabapentin; and opioids or
opioid-like drugs, including oxycodone or tramadol5. An alternative pain reliever for those
experiencing diabetic neuropathy is dextromethorphan, an NMDA receptor antagonist. Although
multiple medications are available to help reduce nerve damage and pain, these treatments are
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not managing everyone. Many people are still struggling and suffering from diabetic neuropathy
and its complications.
OBJECTIVE
The objective of this systematic review is to determine whether or not oral
dextromethorphan provides pain relief in patients with diabetic neuropathy.
METHODS
This review is comprised of three randomized controlled, double blind, clinical trials that
meet specific criteria for the comparison of dextromethorphan for pain relief in patients with
diabetic neuropathy. The first trial was a RCT double blind study comparing pain relief between
dextromethorphan and a placebo. The second RCT double blind study examined the efficacy of
dextromethorphan and an active placebo. The third RCT double blind study assessed 3 different
study groups. Two groups received a drug combination, while the third group received a
placebo. The two combo drugs used were dextromethorphan30/quinidine 30 (DMQ 30/30mg)
and DMQ 45/30mg. The only difference between these groups was the strength of
dextromethorphan. The populations within all of these trials consisted of adults older than 18
who had daily pain of at least moderate intensity, for at least 50% of the day, for a period of 3
months. The populations excluded from these studies were patients younger than 18 years old
and patients who were experiencing any other type of pain not related to their diabetic
neuropathy.
Key words used in the research for these studies were dextromethorphan, diabetic
neuropathy, and peripheral neuropathy. All articles used in this research were peer-reviewed
journals and were investigated via key words on Cochrane Library Collection and PubMed.
Selection of the articles researched had to meet several inclusion criteria: material contained in
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the article had to be relevant to the proposed clinical question, the article’s publishing dates had
to be from 1996 to present date, and the articles had to be presented as a patient oriented
outcome study. Exclusion criteria included articles published prior to 1996, articles that focused
on disease oriented outcomes versus patient oriented outcomes, or articles that included
participants suffering from any other type of pain. Statistics used within two of these studies
included: control event rate (CER), experimental event rate (EER), number needed to treat
(NNT), confidence interval (CI), relative benefit increase (RBI), absolute benefit increase (ABI),
and p-value. The other study used p-value, confidence interval, and paired t-test. Below, Table
1 displays the demographics and characteristics of the studies reviewed and used.
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Table 1: Demographics and Characteristics of included studies
Study
Type
#Pts Age Inclusion
Exclusion
(yrs) Criteria
Criteria
6
Nelson
Double 32
18-Complete pain -Presence
(1997)
blind
85
diary
of any other
RCT
y/o
-Diagnosis of
pain
diabetes
condition
-Distal,
-Unstable
symmetrical
disease
DN
process
-Liver or
kidney
disease
-Concurrent
use of
MAOIs
7
Sang
Double 55
≥18 -Experiencing
- suffering
(2002)
blind
y/o
moderate pain from any
RCT
daily for over a other type
minimum of 3 of pain
month span
-Liver,
due to DN
cardiac or
-Previously
kidney
failed trial of
disease
TCAs for at
-S&Sx of
least 2 weeks
any central
or development neurologic
of side effects
disorder
-Glucose
-Concurrent
control
use of
-Stable
MAOI
analgesic
regimen for 2
weeks
1
Shaibani Double 379 ≥18 -Diagnosed
-Failing ≥3
(2012)
blind
y/o
with diabetes
pain
RCT
type 1 or 2
medications
-Documented
-Require
glucose control narcotics
-Experiencing
for pain
painful diabetic control
distal sym.
-Sensitivity
sensory/motor to quinidine
polyneuropathy or opiates
for at least the -Prior tx
3 months prior with DMQ

W/D Interventions
6

Two six-week drug
treatment periods (one
with the active drug and
one with the placebo),
separated and completed
by a week washout
period.

9

Two randomized placebo
controlled, double blind
trials took place during
this study. The first study
was an “efficacy trial”
where the effects of
dextromethorphan,
memantine, and the active
placebo (lorazepam) were
compared. The second
study was a “doseresponse” trial of
preferred active drug in
participants. Their pain
and side effects levels
were assessed 2x/week.

137

All patients were
randomly divided into
one of three groups
Dextormehorphan/quinine
(DMQ) 45/30mg, DMQ
30/30mg, and a placebo
group. Over a 13 week
period pain relief was
assessed with 4 different
mechanisms.
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OUTCOME MEASURED
Although each study had their own method of measurement, the outcome measured was
the same. This outcome was pain relief. In the Nelson study, pain relief descriptors were
compared with the placebos using a Mann-Whitney U test. The primary outcome variable was
the participants’ mean pain rating during the last 7 days of the group taking dextromethorphan
compared with the last seven days of the trial group taking the placebo. Outcome was calculated
using a paired t-test. The second trial, Sani study, used a category rating scale to measure pain
relief. Finally, the Shaibani study used a 5-point Pain Intensity Rating Scale, which assessed
baseline pain and pain on days 15, 29, 50, 71, and 92 during a clinical visit.
RESULTS
In all three RCT double blind studies, the efficacy of dextromethorphan is compared with
a placebo or both a placebo and an alternative medication. In the Nelson study, a total of 14
patients entered the study, of which 13 completed both treatments. The patients in this study,
first started with a one-week baseline period, followed by two six-week treatment periods, which
was separated by a one-week “washout” period6. When given the dextromethorphan, the
patients first started with 120mg QID and titrated to a maximum of 960mg daily. While one
group was randomly given dextromethorphan, the other was receiving the lactose placebo6.
Every 3 days, a nurse contacted the participants to titrate medication dosage and to assess pain,
adverse reactions, and compliance6. Every three days the patients increased their medication by
30-60mg/day unless adverse reactions began affecting daily activities, the patient reported
complete pain relief, or if the maximum dose was reached6. During the last two weeks, week 5
and 6, the highest well-tolerated dose was kept at a constant level6.

Lundberg,	
  Dextromethorphan	
  and	
  Diabetic	
  Neuropathy	
  	
   7	
  
During the last week of the study, dextromethorphan reduced pain by a mean of 24%
compared to that of the placebo6. Scores were determined by measuring pain relief on a 13-word
descriptor scale. The results showed that while on dextromethorphan, pain was relieved: “a lot,
4; moderate, 3; slight, 4; none, 2; and pain worse, 0;” versus the “placebo: a lot, 0; moderate, 0;
slight, 6; none, 5; and pain worse, 26. No participant admitted to full pain relief with either
treatment period6. The means of the global scores were: dextromethorphan: 2.7 and placebo
1.36. Those who reported moderate or better pain relief with dextromethorphan described their
lowest pain experience while on the highest dextromethorphan dose tolerated6. As shown in
Table 2, when measuring pain relief, researchers calculated a p-value of 0.01, indicating that this
study was statistically significant.
Table 2: Nelson Study: Dextromethorphan vs. Placebo6
Outcome measured p-value Confidence Interval (CI)
Pain relief
0.01
95%
In the Sang Study, 23 participants were selected for the study, 19 of who completed the
study in its entirety7. In this RCT double blind trial, the patients participated in two different
trials. The first was an efficacy trial, which consisted of a three period, three treatment balanced
Latin square design which assessed the relationship between the maximally tolerated doses
(MTD) of dextromethorphan (MTD=960mg), memantine, and an active placebo (lorazepam)7.
The second study was a dose-response trial, which consisted of a four period, four treatment
Latin square design in “responders” comparing the pain relief recorded at different stages of
treatment dosing (0, 25, 50, 100%) up to the maximal tolerated dose determined in the first trial,
versus the active placebo7. During the trials, all medications were dispensed in identical
appearing capsules7. Each treatment period consisted of a one-week baseline period followed by
a seven-week period where the medications were given 4 times throughout the day7. A nurse,
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also blinded to the study drug, contacted the patient approximately twice weekly to assess the
adverse reactions and to titrate the medication. After the 7 weeks, the patients completed a 2week washout period before beginning the next trial7. At the end of the efficacy trial, pain relief
was measured using a category rating scale7. When comparing the efficacy between
dextromethorphan and the active placebo; 13 of 19 patients reported moderate or better pain
relief with dextromethorphan compared to the 7 of 19 who reported moderate to better pain relief
with the placebo7. The findings at the conclusion of the dose-response trial were: zero patients
reported moderate or better pain relief with placebo (0% MTD), one patient reported pain relief
with 25% MTD, six with 50% MTD, and ten with 100% MTD7. Although researchers found
that 25% MTD of dextromethorphan was not statistically better than lorazepam, it was concluded
that both 50% and 100% MTD of dextromethorphan was statistically better than the placebo7.
Below, Table 3 compiles a summary of the Sang study’s findings. Using the control event rate
and the experimental event rate, the relative benefit increase was calculated as 84% and the
absolute benefit increase was found to be 31%. Using the ABI, numbers needed to treat was also
calculated. Numbers needed to treat for this study was 4. This means that for every 4 people
treated with dextromethorphan, one more had pain relief compared to the control group.
Table 3: Sang Study: Dextromethorphan vs. Active placebo (lorazepam)7
CER
EER
RBI
ABI
NNT
p-value
Placebo
Oral
Lorazepam Dextromethorphan
0.37
0.68
0.84
0.31
4
0.12
In the Shaibani Study, 131 participants were randomized into the Dextromethorphan
45/quinidine 30mg (DMQ 45/30) group and 123 were randomized into the placebo group1. In the
DMQ 45/30mg group, 131 participants started, but only 79 completed the study1. Of the 123
who were in the placebo group, only 89 completed the trial1. Throughout the study, all of the
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participants completed a 13-week, phase 3 RCT where four pain rating scales were applied daily
using diaries and five-clinic visits1. On days 1, 15, 29, 50, 71, and 92, a 6-point categorical Pain
Relief Rating Scale was used to record and classify the relief of their leg pain, compared with
baseline1. The primary analysis assessed the profile of daily Pain Rating Scale scores of the
experimental group compared to those of the control group using a mixed-effects regression
model1. Researchers found that in both the overall profile and on days 30, 60, 90, the DMQ
45/30mg was statistically significant in pain relief when compared to the placebo1. Researchers
also saw a 30% Pain Rating Scale score reduction for 83% of the patients on DMQ 45/30mg
compared to a reduction in only 61% of the patients on the placebo1. Finally, 66% of
participants taking DMQ 45/30mg compared to 39% of the placebo group achieved a 50%
reduction on the pain scoring scale1. Table 4, summarizes the results calculated and recorded for
the Shaibani study. Once again, using the control event rate and the experimental event rate, the
RBI and ABI were calculated. In this study the relative benefit was calculated as 39% and the
absolute benefit increase was recorded as 66%. Numbers needed to treat for this study was also
4.
Table 4: Shaibani Study: DMQ 45/30mg vs. Placebo1
CER
EER
RBI
ABI
NNT
Placebo
DMQ
45/30mg
0.39
0.66
0.69
0.27
4

p-value
0.001

DISCUSSION
This systematic review assessed the use of dextromethorphan for pain relief in patients
with diabetic neuropathy. Although dextromethorphan is FDA approved as a cough suppressant,
due to its mechanism of action, it has been found to help relieve neuropathy as well.
Dextromethorphan is an attractive medication because it is a low affinity, non-competitive,
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channel blocking NMDA receptor antagonist6. It is hypothesized that by blocking these
receptors, it would inhibit the abnormal CNS excitation seen in diabetics and potentially alleviate
their experienced pain6. Even though each study reviewed was structured differently, the final
results were similar. As hypothesized, dextromethorphan proved to relieve pain better than its
competing placebo. Therefore, these studies give physicians and patients another treatment
option for diabetic neuropathy.
Even with the successful results of these findings, the studies researched had several
limitations. Between all three trials, the population of participants who actually completed the
entire study was low. The sample sizes 13, 19, and 254 respectively do not represent the
generalized population. Another hindering aspect of the studies was that each study was
conducted and measured differently. While the Nelson study only looked at dextromethorphan
and a placebo, the Sani study also used memantine and the active placebo, lorazepam, which
may or may not have been the placebo used in the other two. Finally, the third study, done by
Shaibani, not only used a combo drug of dextromethorphan and quinidine, but also compared the
results of different strengths of the dextromethorphan given. A final limitation of all three
studies was the lack of investigating the long-term effects of the drug on each patient. As a
cough suppressant, some adverse reactions seen with dextromethorphan include dizziness,
fatigue, abdominal pain, nausea, and potential abuse. However, as a long term high-dose
medication, other adverse reactions may be seen. Changing a drug’s dosage and length of
treatment warrants careful evaluation of the drug before prescribing it. None of the studies
followed the patients long enough to record and track the effects of the drug long term. The
result of the studies is inclusive as an overview for the U.S. population due to several factors: the
trials’ use of unlike controls (different drugs, drug combinations, and strength of drugs), the lack
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of participants who completed all three studies, and the lack of investigation of long-term effects.
Despite the limitations of these studies, hope for a new treatment for diabetic neuropathy still
persists.
CONCLUSION
Diabetic neuropathy is a common medical problem seen in diabetics. Although
numerous treatments are currently on the market for pain relief, many patients are still not seeing
benefits from these medications. Dextromethorphan has recently been tried as an alternative
medication and has been proven to be a safe and effective for pain relief in patients with DN. In
the three randomly controlled, double blind clinical trials that were reviewed, it was found that
dextromethorphan decreased the amount of pain experienced from the neuropathy more than that
of the placebo. Although these trials show positive results statistically in the use of
dextromethorphan as a pain reliever, further studies must be done to warrant the appeal for the
use in treating diabetics. Two main issues that should be addressed in future studies are the size
of the study groups and long-term effects of the drug being investigated. A larger research
population will enable the results to give a better representation of the US population as well as a
stronger validity to the results. Examination of the long-term effects of this particular drug is
important, as this drug was not originally manufactured for pain relief. Detecting, knowing, and
understanding all possible adverse reactions for any medication is very important, especially
when it is being used to treat a chronic condition. Even with the limitations presented, these
three studies give hope for future treatments for the debilitating diabetic neuropathy.
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